SCHEDULE: Bleichroeder Discloses 9.69% Stake in Precision BioSciences

Sentiment:

Beneficial Ownership Report


Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have disclosed a beneficial ownership of 9.69% in Precision BioSciences Inc.'s common shares.

Summary

  • Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach collectively reported beneficial ownership of 1,075,000 common shares of Precision BioSciences Inc.
  • This ownership represents 9.69% of the company's common shares outstanding as of June 30, 2025.
  • Bleichroeder LP, an investment adviser, holds sole voting and dispositive power over all 1,075,000 shares.
  • The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant beneficial ownership stake (9.69%) by an investment adviser and related entities is generally a neutral to slightly positive signal, indicating institutional interest in the company. It does not contain negative information, nor does it provide performance metrics to assess 'better' or 'worse' results.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Precision BioSciences, a company operating in the biotechnology sector. Such disclosures can signal investor confidence or strategic positioning within the competitive biotech landscape, where capital allocation and institutional backing are crucial.

Stakeholder Impact

  • Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.
  • Company Management: Awareness of a large shareholder may influence strategic decisions, though the filing states the shares are not held for control purposes.

Key Dates

DateDescription
06/30/2025Date of event which requires filing of this statement (ownership snapshot date)
08/12/2025Date the Schedule 13G was signed and filed

Keywords

Precision BioSciences, Bleichroeder, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Investment Adviser, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.